B+
Bull case
25%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
OSUR
OraSureCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+71.5
Score
AI commentary
This is a cautious T+3 post-earnings update. Primary company sources are strong and show a mixed print on May 6, 2026: revenue landed above the midpoint of guidance and margin improved, but losses and burn stayed heavy. Market reaction also looks muted rather than thesis-changing: the packet anchor was $3.13 on May 7, 2026, and live price data on May 8, 2026 showed OSUR around $3.06, a low-single-digit move lower after the release. I did not find a reliable post-print analyst revision set from checked sources, so the memo stays monitoring-oriented rather than upgraded.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06catalystPost-earnings setup is now about proving Q2 stability rather than just clearing a low barHigh impact
Q1 revenue of $27.9 million came in above the midpoint of management's prior guidance, core revenue was down only 0.5% year over year, and gross margin improved to 42.3%, but operating loss still widened to $23.3 million. Q2 guidance of $27 million to $30 million keeps the near-term bar centered on holding revenue and margin gains while limiting further burn. [#8-K-2026-05-06] [#10-Q-2026-05-08]
2026-12-31eventFDA review outcomes for Colli-Pee and the Sherlock CT/NG self-test remain the cleanest upside triggerHigh impact
Management's May 2026 investor update says regulatory review is underway for both the Colli-Pee at-home first-void urine self-collection device and the disposable rapid molecular CT/NG self-test following FDA submissions in December 2025. With current core revenue still only stable at a low base, favorable review progress or launch timing would be the clearest path to a sentiment upgrade. [#8-K-2026-05-06]
2026-12-31catalystBalance-sheet support buys time, but rerating still needs core breakeven progressHigh impact
OraSure ended March 31, 2026 with $177.0 million of cash and cash equivalents, and management highlighted a no-debt balance sheet, but Q1 still used $13.9 million of operating cash and the company posted a $22.4 million net loss. The long case depends less on cash alone and more on turning manufacturing efficiencies and new-product launches into a credible path toward breakeven and margin expansion. [#10-Q-2026-05-08] [#8-K-2026-05-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology